Benefit versus Risk in Statin Treatment

American Journal of Cardiology

Volumn 97, Issue 8 SUPPL. 1, 2006, Pages

  Guyton, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FATALITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FAILURE; MEDICAL LITERATURE; MORTALITY; MYOPATHY; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; SURVIVAL RATE;

CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 33645866464     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.12.016     Document Type: Article

References (25)

1. Gotto Jr. A.M. Statins, cardiovascular disease, and drug safety. Am J Cardiol 97 suppl 8A (2006) 3C-5C
2. Law M.R., and Rudnicka A.R. Statin safety. a systematic review. Am J Cardiol 97 suppl 8A (2006) 52C-60C
3. Wilt T.J., Bloomfield H.E., MacDonald R., Nelson D., Rutks I., Ho M., Larsen G., McCall A., Pineros S., and Sales A. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164 (2004) 1427-1436
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals. a randomised placebo-controlled trial. Lancet 360 (2002) 23-33
5. American Heart Association. Heart and Stroke Facts 2005 Statistical Update. [American Heart Association Web site.] (2005). http://heart.org/presenter.jhtml?identifier=3000090 Available at: http://heart.org/presenter.jhtml?identifier=3000090. Accessed August 29
6. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke. systematic review and meta-analysis [review]. BMJ 326 (2003) 1423
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
9. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., Packard C.J., and West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
10. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
11. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
12. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., and Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
13. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., and England J.D. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
14. Tolman K.G. The liver and lovastatin. Am J Cardiol 89 (2002) 1374-1380
15. Bays H. Statin safety. An overview and assessment of the data-2005. Am J Cardiol 97 suppl 8A (2006) 6C-26C
16. Bottorff M.B. Statin safety and drug interactions. clinical implications. Am J Cardiol 97 suppl 8A (2006) 27C-31C
17. Jacobson T.A. Statin safety. lessons from New Drug Application submissions for marketed statins. Am J Cardiol 97 suppl 8A (2006) 44C-51C
18. Davidson M.H., Clark J.A., Glass L.M., and Kanumalla A. Statin safety. an appraisal from the Adverse Event Reporting System. Am J Cardiol 97 suppl 8A (2006) 32C-43C
19. Cziraky M. An assessment of the safety of lipid-altering drugs using an administrative claims database. Am J Cardiol 97 suppl 8A (2006) 61C-68C
20. US Food and Drug Administration. FDA response to a Public Citizen petition regarding Crestor (2005). http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf March 11, 2005. Available at: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf. Accessed August 29
21. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
22. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La G.L., Gurwitz J.H., Chan K.A., Goodman M.J., and Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
23. Montori V.M. Evidence-based endocrinology. how far have we come?. Treat Endocrinol 3 (2004) 1-10
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2496
25. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239